{"id":"W3000712048","doi":"10.1016/j.jacc.2019.10.057","title":"Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":572,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; St. Michael's Hospital; University of Alberta","funders":"American Regent; Esperion Therapeutics; Duke Clinical Research Institute; Astellas Pharma; Eisai; University of Toronto; Daiichi-Sankyo; Bayer HealthCare; European Commission; AstraZeneca; Amarin Corporation; Eli Lilly and Company; University of Alabama; Regeneron Pharmaceuticals; Boston VA Research Institute; Medicines Company; University of Alabama at Birmingham; Bristol-Myers Squibb; Cleveland Clinic; Novo Nordisk; MyoKardia; University of Pennsylvania; Belvoir Media Group; Servier; Gilead Sciences; York University; Pfizer; Heart and Stroke Foundation of Canada; HLS Therapeutics; GlaxoSmithKline; CSL Behring; Amgen; St. Jude Medical; Kowa Company; Sanofi; American Heart Association","keywords":"Medicine; Alirocumab; Acute coronary syndrome; Cardiology; Internal medicine; Lipoprotein(a); Lipoprotein; Cholesterol; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001607417,0.000231445,0.002704485,0.0001178761,0.00005124012,0.000002389754,0.000237587,0.0000915313,0.00000672969],"category_scores_gemma":[0.0003541074,0.0001367661,0.002248047,0.0003861063,0.0005392444,0.00004220788,0.000134451,0.0005303876,0.000001683385],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005450767,"about_ca_system_score_gemma":0.0001861265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004903681,"about_ca_topic_score_gemma":5.331278e-7,"domain_scores_codex":[0.9967722,0.001339331,0.0006317988,0.0002421545,0.000769588,0.0002449145],"domain_scores_gemma":[0.9979322,0.000183773,0.0007578757,0.0006942523,0.0001974988,0.0002344008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09516831,0.000263074,0.5066939,0.003657361,0.1295009,0.03060609,0.0005398625,0.003531859,0.008586813,0.0001130608,0.006500841,0.214838],"study_design_scores_gemma":[0.0106447,0.05707038,0.8498917,0.0005575331,0.01324159,0.04648406,0.0003038968,0.00005286714,0.01004642,0.00006221042,0.01125283,0.0003918366],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922509,0.005320226,0.0002297963,0.001019903,0.0001930853,0.000688286,0.0001305578,0.000007028565,0.0001601984],"genre_scores_gemma":[0.9971139,0.001808461,0.0002945841,0.0003769996,0.0003456733,0.0000148185,6.615209e-7,0.00003159659,0.000013296],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3431978,"threshold_uncertainty_score":0.5577161,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006028763705398898,"score_gpt":0.2373177668374906,"score_spread":0.2312890031320917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}